HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON, March 13, 2019 – Akari Therapeutics, Plc …

[Read more...] about Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics’s Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA) NEW YORK and LONDON, November …

[Read more...] about Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit